KROS Keros Therapeutics Inc

Price (delayed)

$34.99

Market cap

$815.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.18

Enterprise value

$560.64M

Highlights
KROS's EPS has surged by 77% year-on-year and by 26% since the previous quarter
The debt has contracted by 33% YoY and by 11% from the previous quarter
The company's net income has shrunk by 109% YoY and by 7% QoQ
The revenue has dropped by 100% year-on-year

Key stats

What are the main financial stats of KROS
Market
Shares outstanding
23.3M
Market cap
$815.16M
Enterprise value
$560.64M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.28
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$48.49M
EBITDA
-$47.86M
Free cash flow
-$39.61M
Per share
EPS
-$2.18
Free cash flow per share
-$1.71
Book value per share
$10.67
Revenue per share
$0
TBVPS
$11.09
Balance sheet
Total assets
$257.73M
Total liabilities
$9.36M
Debt
$797,000
Equity
$248.37M
Working capital
$247.03M
Liquidity
Debt to equity
0
Current ratio
28.6
Quick ratio
28.53
Net debt/EBITDA
5.32
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-23.8%
Return on equity
-24.8%
Return on invested capital
N/A
Return on capital employed
-19.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KROS stock price

How has the Keros Therapeutics stock price performed over time
Intraday
2.61%
1 week
-6.22%
1 month
-14.64%
1 year
-2.72%
YTD
-50.4%
QTD
-17.61%

Financial performance

How have Keros Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.99M
Net income
-$48.55M
Gross margin
N/A
Net margin
N/A
Keros Therapeutics's operating income has plunged by 184% YoY and by 11% from the previous quarter
The company's net income has shrunk by 109% YoY and by 7% QoQ
The revenue has dropped by 100% year-on-year
The gross profit has plunged by 100% YoY

Growth

What is Keros Therapeutics's growth rate over time

Valuation

What is Keros Therapeutics stock price valuation
P/E
N/A
P/B
3.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
KROS's EPS has surged by 77% year-on-year and by 26% since the previous quarter
The price to book (P/B) is 43% lower than the last 4 quarters average of 5.6
KROS's equity is down by 5% since the previous quarter
The revenue has dropped by 100% year-on-year

Efficiency

How efficient is Keros Therapeutics business performance
The company's return on assets rose by 38% YoY and by 19% QoQ
The ROE has grown by 30% from the previous quarter

Dividends

What is KROS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KROS.

Financial health

How did Keros Therapeutics financials performed over time
The quick ratio has contracted by 23% from the previous quarter
The company's current ratio fell by 23% QoQ
The debt is 100% less than the equity
KROS's debt to equity has soared by 100% year-on-year
The debt has contracted by 33% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.